Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
inhibikase therapeutics完成了“201”試驗的2期研究入組,評估risvodetinib治療未經治療的帕金森病
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
inhibikase therapeutics完成了“201”試驗的2期研究入組,評估risvodetinib治療未經治療的帕金森病
譯文內容由第三人軟體翻譯。